Company attributes
Other attributes
Carmine Therapeutics is a company that is developing novel types of gene therapies utilizing extracellular vesicles produced in the laboratory. It is pioneering a new class of non-viral gene therapeutics which is based on red blood cell extracellular vesicles, combined with proprietary payloads.
In June 2020, Carmine inked a research alliance with Takeda Pharmaceuticals worth up to $900 million to develop non-viral gene therapies for 2 targets.
Carmine was founded by Esco Ventures X, Professors Harvey Lodish (Whitehead, MIT), Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme and Millennium Pharmaceuticals, is also Chair of the Scientific Advisory Board of Carmine.
